Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by SanFrancisco99on Apr 28, 2015 3:54pm
337 Views
Post# 23673184

First Time

First Time What an amazing year this has been (so far) for Resverlogix.

The assortment of business news articles quoting Don saying that they are "in discussions" with multiple pharma is quite interesting.   And quite unique.

While it can be said that Don has used the word "discussions" before, I don't personally recall a single instance of him talking about this so clearly and openly with the business press.   

I would find it possible that he is signaling the market....   just like he signaled the market earlier this year that they were in talks regarding a regional deal.  That prophesy came true a few weeks later, of course, in the form of the China deal.

So why is Don talking about this now?   Could it be that the talks have proceeded further along than in the past?   Could it be that he sees a deal as being a possibility in the near future and he doesn't want people to get caught off guard with that?

I've met Don several times.  I find him to be an honorable guy and an honest guy.  I think he says what he means - and I think he's learned to be very careful with any statements he makes - especially to the press.

What this all means, I can't tell you.  But it is very interesting to think about.

Things are definitely moving forward at a fast pace with RVX.  The company is about to launch multiple Phase 3 trials.  That's pretty much a dream come true for many of us longs.

Narmac's Seabiscuit is gaining speed around the bend.  Maybe the photo finish will come sooner rather than later.  When the CEO starts signalling in that direction, it is something to pay attention to.

GLTA.  IMHO.  DYODD.  














Bullboard Posts